NNOX - Earnings call transcript Q2 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and thank you for standing by. Welcome to the Nanox Second Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Mike Cavanaugh, Investor Relations. Please go ahead.

Mike Cavanaugh

Good morning, and thank you for joining us today. Ltd. Imaging Nano-X today, Earlier released financial June XXXX. quarter for the ended XX, results on is section release currently the The available website. Investors company's of the me Chief Meltzer, Chairman; With Erez Officer are Acting and Chief and Officer. Financial Executive Daniel, Ran today

current may not statements are activities, Before other may results, everyone a difference management the be those subject we that manufacturing research are in this that and limited Commission. of company's any will remind company's expectations regarding matters. should as cause future. statements commercialization such during that include statements development, filings to, the get with forward-looking management's uncertainties upon would regulatory of making as the risks, that to and the and and representing I today based not be call are Securities not Exchange started, described date. Factors These but process relied like operations statements be company's include, in to views and and Therefore, financial the assumptions these as updated subsequent on

or to and gross the that, profit, expenses turn non-GAAP non-GAAP per expenses, and Erez non-GAAP primary non-GAAP also marketing development net attributable to measures provided revenue, sales now and of gross Meltzer. to research general to our is shares, GAAP certain expenses with call I'd non-GAAP the non-GAAP to share. to profit other financial income reconciliation non-GAAP will We information measures to margin, gross provide non-GAAP release, press expenses, non-GAAP cost like administrative non-GAAP over with differences investors. A being refer the additional of and With ordinary loss non-GAAP loss

Erez Meltzer

support and rest while efforts to us and appreciate your advancing the for clinical U.S. of deployment progress the mission. expand period of of commercial has of as the today. we XXXX also world. through we always, products our our And as joining in a been Nanox value our you strong our Thank the continued continue

not other only deployment the accelerating Nanox Nanox.ARC of also of elements the system, the value-added Nanox.AI. are full but footprint including We of expanding the solution,

thoughts in begin recent mentioned detailed providing will discussion updates, As ongoing updates coming with of I calls, call call our to will Nanox.ARC share who previous committed call deployments, insights which results. then introduction investments further clinical prepared system, a over X. and in the I'll will my periods. financial cover Nanox.AI closing our will on QX and we'll review the comments, to commercial achievements, new which the turning turn to Q&A to advancements, After Nanox.ARC updates I regulatory an our our before CFO, our over session. the few a Ran, I'm

lot a discuss, let's get to have so We started.

of overview for indication will which regulatory including a on expand share just our cleared, positive systems in an last that XXX(k) the week, believe from our provide commercial impact will intended imaging. our for submission Once clinical is system current will near-term with chest. for we FDA, general Nanox.ARC current commercial the MSK, submission expand begin use significantly submitted some to updates, the general and progress, I'm a use, the to I indications new Before which tomosynthesis I efforts. have to Nanox happy the

anatomies was work upgrade submission with include noting clinical the post Nanox.ARC chest FDA up the Nanox.ARC much centered that without software As standards. all submission. The chest subject approvals. requisite bring the can various will necessary to body MSK, to of we clearance be means it clear, performing required To for to done you accompanied simple and know, be new deployed is of This clinical hardware around scan intended has that are data suitability updates is the to regulatory and pathologies. some and will systems to and the and units the been recently [indiscernible] is for support the software currently all worth the new by ready have that capabilities installed be that have FDA and indications abdomen, clearance, remotely Nanox.ARC a

stages, Additionally, after passing from obtaining completing the MDR successfully the ISO technical the including and BSI certification XXXXX audit.

now with updates in the We as assured, are are available. as secure our advanced region. Notified will mark to Body CE provide soon Rest EU they for stages the we

the Turning and next our which to second now deployment efforts commercial quarter. in global continued

is imaging Nanox.ARC of centers, with our increase diligently footprint physicians working and regulators Our team technology. to

care and we The newest As expect U.S., deployment the X various the being would state color stages of U.S. number X and quarter, of our growth the To give and and to I to that awaiting our during deployment. our largest which second now approvals, the industry. are executes in in on chains facilities today's have call, spread California, this there imaging deployment, team operating dozens grow commercial Delaware including health add of deployments in as of plan. more across like the the across units installed Nanox.ARC are in U.S. prominent one system shipment are states, we

are U.S., of received obtaining approval. deployed scanning and in commercial the activity the the sites body some regulatory accelerating. certification have begun scan have state to corresponding patients. This process in from Additionally, the is Others of

up additional prospects EOB. the XX received to of we in recently management ramping have have care We current Since pipeline. shown those up XXXX, in per leads with and for been we the received indications CPT XX as example, U.S. backlog process as good U.S. and reimbursement XX day. validation scans today, the favorable For March of sites one of of targeted

imaging our main short With but are all not that convert, this to understand outpatient continue these period, grow leads and XX with a medical very in we will team's will segments orthopedic time. that of chains confident very and imaging centers, centers. I'm pleased being over progress the such We commercial

the Mexico We systems are ready in for to also awaiting deploy with Nanox.ARC the shipment. the import license first

months expected deployed use. deployment approval both for commercial Additionally, ago. and and obtained months upcoming several units in we there fully are opportunity this pursue X able in to the is We're clinical another Israel, AMAR as

accelerating. of And Importantly, an clinical scans. in X.XX all number scans commercial is of globally daily July, we work for both accomplishing average and the system, experienced patient deployed Nanox.ARC last scans

learn XX% may global follows: interesting -- I clinical part XX% commercial is think over of hand; as But that scans vary chest; and time. to distributed and XX% the it these by course, XX% body leg; are from indications spine.

we are quarter, and team have interested, For and teams. those sales infrastructure chest technical U.S. to strengthen samples our of clinical support effort, to that website, our pathology. To also some new deployments on we our continued our accelerating the adding during including you

to strategic is of Looking collaboration dedicated execution the infrastructure ahead, country. commercial Nanox the our accelerating and in future

advantage Our patient practices not with Nanox.ARC, mission cost-effective elevates care. is solution a that transformative capabilities, a with care provides to imaging an accessible also advanced overall diagnostic only provide health but imaging

accelerate We Nanox.ARC health part flow referrals of diagnostic providers are from workflow. tomography a to digital as imaging working care steady for of their

will to value-added is key our our multiple Nanox. The advance generating the We boost locations, initiative utility efforts demonstrating of all we clinical the and utility data, is of of fuller, important large the also reason volumes countries for in efforts. it can simple, significantly show Nanox.ARC indications if a demonstrating other the commercial wider a Nanox.ARC, continue of data range for

as at Hospital the diagnostic a company to used diagnosis diagnosis supplemental images site determined a scanning The for white at findings. to been the to begun part And dozens a this workflow. Furthermore, For achieving all patients has trial tool generate faster been exactly this the in final depiction the scanning scanning example, has when reason. the of MScale published multi-site studies. high time Nanox.ARC already to standard and has trial experience while of The hospital's sites the clinical activity. operational, UGMC of were clinical standard as Beilinson There was be The in Israel of installed been enabling completed x-ray is participating patients Hospital compared as previously are optimal The preparation paper a Shamir accelerating now this is study the our system, enabling trial has few trial workflow, value-added join Nanox.ARC patient multisite data. CT-based Nanox.ARC in quality, concluded held announced in recruited the patients. recently. multisite quicker clinical and with second gaining that we the as the tool to and

even Our lesions fraction be [ investigated. technology may have resolve compared per can increase radiation to ] to depiction the and of images [indiscernible] experience at and further without of should a occult questionable prior lesions, CXR. capability localized for dose, eliminate chest diagnostic CT improved characterized accuracy study the need cost Its radiologist an

more our see paper our white For more on section website. information,

business. AI our to Turning

Tomography, Computed multiple in month, called SCCT last at HealthCCSng the XXXX we solution Meeting. announced Just of our Nanox.AI Society Cardiovascular highlighted that scientific presentations Annual cardiac was

systems, at these Einstein In identify higher tool with XX-fold are study in Women's these esteemed scoring Hospital, patients its Mass aged along found to founded approach AI our of that encouraged noncontrast Traditional and the XX be AI levels above all care. was mortality level CAC CT as risk incidental previous scan patients or preventive disease implemented patients, reported a the outcome. A, and of cardiovascular lipoprotein CAC adverse detection, cause measurements at-risk on valuable cardiac associated implementation the validation immune-mediated diseases. by promote to care the was chest in by A of potential previously over correlation years. At and scans this over patients solution XXX the HealthCCSng scans X cardiovascular care its Hospital and by may that part Brigham patients with quantifying lipoprotein had patients conducted units. medical used implemented as full Gen and be for system, and statistically continued significant our Hospital, of identify a a inflammatory in increase HealthCCSng the Jefferson real-world the suggesting and year of to Agatston through quantify cardiac than of of is Israel, of and difficult identify We electronic calcification artery Nanox.AI was the A early HealthCCSng in Health, can coronary Beilinson XX% help new and analyze reported of risks. After a who there patients. XXX risk cardiovascular Corewell in installed coronary record being factor between this used was studies XXX in Hospital solution atherosclerosis with CT of clinical and in first health

doing the study, Weber is was As as Investigator of in outcome. out, the patient overall Nanox.AI a support solutions author to clinical continuum the to is associated signed earlier at Brittany to work dynamic Young potential care Award drive lead be identify valuable this that of the better health to Winner well. Nanox with Annual and talent use as Meeting risks declared the helping proud

with Nanox.AI Health are the start, for Health feedback signed Additionally, and the far. positive we previous been Covera a and great agreements has off very to Dandelion thus

accessible are to customers. AI of range broader continually expand working We make our to and it a footprint

focused Our on and reach a ongoing efforts and our and enhancing AI innovation ensuring wider development they are audience. benefit solutions

is I there at about. be think I Nanox when of a all say of lot I to speak us can excited

Looking looking future improve ahead meet to near we Nanox, are needs. to always of market the and

that ARC needs also even our FDA which offering. At I'm expand with easy we one smaller including imaging to using important systems we plans expansion to to an product feature, new dynamic setup time Nanox.ARC to our fact, system for meet existing have current in needs that clinical expand over needs is publicly high Once of among tuned system working touch will Nanox Nanox.ARC made cleared, I term pleased on can at than X refine case. developing further this anticipated customers, for Listening which technology time the will new step also future I'm available on constantly detail. the about efforts, as it There deploy company first Stay on on our an enhancing market the functionality. additional on will use and level, share the time data be to a will differentiators. Nanox is developments. designed very In another new image program rapidly first with and marketed space. be centers Nanox.ARC synthetic report use design, of evolving who systems, that the units, we changes the constantly in technology our no are enhancement system, product also Nanox in to are government offering based towards our we are customer the clinical Nanox.ARC X-day an detail not will future for The during use well Nanox.ARC and submit, for Amongst and available and able and development current more feedback, is next which technology that every the share to the entity the are planning as future focused generate their OEM intend Nanox our solution. clearance. options our long footprint our with To and our completion which of system partners key we cases. the and share currently be plug-and-play well XD. Please the X, the phase Nanox.ARC others underway of called the with of are via ongoing be that to to emitter tube are U.S. the event, X hospitals utilizing to website. entity note novel different, will along existing

move half of the year. tubes optimistic are we We second will in towards this prototyping

Regarding of on RAD significant U.S. of as we leveraging a services, deployment client network teleradiology our part a our U.S.A. our are plan. radiologists based

On in emitters. functional we the mass production CSEM, finalized of have our with development second high-yield resulting phase a in the wafers front,

to secured transitioning and are supply for novel our the source a of confident second emitters. we We production have readiness

for completed today. a covered new integrated our utilizing of has I've lot initial their ground emitter Varex tubes prototype to testing be Nanox.ARC. into

I'll to the Daniel hand So over with that, financials. to Ran? review call Ran our

Ran Daniel

reported million in non-GAAP increase million $X.X gross comparable loss. Revenue compared net gross period for $X.X basis of and teleradiology Erez. will Revenue quarter $XX.X to the as a and the profit reported non-GAAP of development basis and decrease XX% margin compared XXXX, $X.X the a on million, period, $X.X for and was for X% of the non-GAAP gross on comparable a million approximately $X.X period reported loss and mitigated administrative compared loss quarter on on represents was a of The which services period net increase the largely $X.X the period period for on profit as the XXXX reported gross for a comparable the $X.X in in million loss reported a second a of million was We of due the margin comparable period. million basis the and GAAP reported for of the a a an the period. the which Thank approximately financial million gross the of to GAAP income, Non-GAAP $X.X for period. you, for a profit the $X.X reported basis a basis, decrease with million the decrease periods period as reported basis. to loss GAAP $X.X I'll non-GAAP million, was loss margin which in a of represents periods. Non-GAAP gross second as was GAAP reported compared to XX% comparable with million gross by basis the of approximately which a and represents profit which to of refer period, gross the the margin $X.X in profit from in a a of gross of company's comparable $XX.X teleradiology gross GAAP comparable comparable $X.X I both profit the to company's a and was a was in refer XX% an on services of million research gross expenses, revenue of on million in million million loss a of expenses, general and which $X.X company's a of

and of generated solutions in reported the $XX,XXX $XXX,XXX revenues of of revenue period, through sales comparable AI to compared the its the in company amount the period. as During the

a loss the U.S. period. was million of generated expenses comparable of period, million. decrease systems of million salaries the the periods to compared million decrease regulatory of XD comparable development legal which with from class wages, in reported million million, revenues and our sales the revenues on reported The insurance in the the to expenses to and finalization the in in of systems, were to and to of of amount for a The sales million period action decrease $X.X decrease of During million as expenses our period of million of through that due Sales the in Africa. Research company a Nanox.ARC the the basis. gross and the period. and $X.X and settlement the GAAP and SEC was were and deployment of million $X.X $XX,XXX a sale for in mainly the reported decrease a premium the million deployment non-GAAP are of stem cost million investigation, for research amounted in $X.X of our million. the imaging Those related decrease the and share-based largely marketing administrative the $X.X and its of and compensation to and as $X.X General the the were liability a directors in the in $X.X as comparable expenses systems $X.X and and $X.X decrease expenses in due and $X.X $X.X largely in $X.X compared $X.X development a a result amount reported of officers activities.

reported net million period. loss comparable was increase expenses to offset million which non-GAAP our of in our a of income, decrease of due $X.X non-GAAP an gross in in by period in loss Our a non-GAAP of $X.X was operating was profit. $X.X ordinary and million interest a million for to decrease attributable non-GAAP mainly $X.X net as decrease the million to $X.X compared $X.X The shares the million of non-GAAP

our sheet. to balance Turning

and a equipment from loan securities equivalents, and XX, June and million had a we $X.X cash marketable XXXX approximately $XX.X of cash, bank. restricted deposits of of of ended net $XX.X property million million. XXXX, quarter with We the second we As a had

had shares XXXX, I outstanding. million With that, over call XX.X of back approximately As the hand June XX, to Erez. we will

Erez Meltzer

Thank you, Ran.

our commercialize of As the executing solution Nanox.AI ] well into we by medical the second workflow. [ integrating on strategy continuing enter to remains system team XXXX, focused our half growth as Nanox.ARC as

clinical our to vision segments hospitals scan-to-diagnosis needs within aligning health strategic accelerating AI like clinics. We extend globally. execution efficient orthopedic care Nanox the with deliver future dedicated infrastructure seamless a more and beyond urgent and solution, leveraging smarter units technology commercial underserved and with is a of for care collaborations outcome Our patient in focus on to enhance Nanox the to innovation is U.S. targeting

mission not is that Nanox.ARC, care overall patient Our provide accessible practices health to imaging the also only diagnostic a imaging an with advantage provides advanced transformative care. but solution capabilities, cost-effective elevates with

conclude remarks fellow our Before their support my mission. thank like and for customers we colleagues, to Nanox shareholders of and today, our I'd

insights As you a open more to now let's forward upcoming and operator, and always, I'd Nanox.ARC make of that, I'm questions. to the call comment. to like available the X with second, meet sharing Operator, the X events. pause for you can look With for

Okay?

Operator

sir. Yes,

Erez Meltzer

Okay.

So solution, additional upgraded to in The with X happy I'm version an announce X.X, calcium. solution, an we version in today, that calcium CAC received artery AI HealthCCSng HealthCCSng calcium which exact clearance is version output. corresponding coronary detection CAC score of an said, category generates coronary and advanced upgraded assessment calcium, introduces the categorization just of of version as cardiac physicians in for we X.X, addition empowering of to everything cardiac the FDA another

For us, from to solution. AI our pleasing for very the is receive validation cardiac further FDA it regulatory

for open will that, the thank And with now call you. -- we questions. So the turn

Operator

Instructions] [Operator

of with Our first Cohen the line question Jeffrey Ladenburg. from comes

Jeffrey Cohen

you sense give are when wondered, regarding the I mostly quarters? far are? on you imaging coming over could you units U.S. placements imagine XX And where about Could and training how So for looks as XX and little bit a leads. your sales us these backlog of spoke firstly, actually funnel upon on that a I domestic expand as they

Erez Meltzer

Okay.

to time, XX; of of think imagine, in more can deployment. number that triple, growing the stages than mentioned we last the you number I was right So various as now,

already regulatory, are over they are gave, which spread the dozens the that that We state that are few because indication for last the for and that approval, in have believe which few we approvals are probably installed are beginning A deployed. states approvals. And states we X a be X waiting the the we where by the XX to of to the be are. them end year, wanted we of XX in and leads we and the getting are process, the of favorable waiting that's to targeted

Jeffrey Cohen

the in with Could far on Could well congratulations addition a these then news a the to at reimbursement tomo And you about them for other facilities? talk indications? testing. you it. bit XXX(k) general calcium general got as little And associated as as for today Okay, talk about codes score.

Erez Meltzer

Okay.

So with end. -- maybe I'll start with the

based scans is -- speak those on CPT With we right the reimbursement basis the for that this tomo reimbursement And is the reimbursement to now, what for submitted the about code, the XXXXX. is their of which reimbursement. the

We I indications have think, already than from from insurers. insurance -- that X, received only more

-- So this and grow. continues to

together. The numbers we model are put that that of in line were the received

we we now, have right only the to -- what and whole so in that the to system for scoring submitted time body, a past CCS received seems the of basically, indications, clearance, have that it's one we With going so is that for -- not submit or So sites the this additional to we the by only are that the we're especially We calcium this but indicated not is the the the -- in U.S., get -- submit it's -- how the the whole chest. the it of that body, rest rest using the basically especially mind the everything. Bear this body spread are to you can of they're ready body is them. and on of various and and the the gave we indication the this we see And received a we the I fact the scan a gave indications, world are part indication were the clinical in all in percentage it is that we that going year that have the the profitable. submission today, global then we I clinical chest using today, the chest, line addition including world, gave able in call between new the parts that even respect for of of that model the the CE, based the of the clinics I the of installed, hardware to in anatomies XXX(k), to the part body that in the whole major and on others it are similar basis. and including decided or

Jeffrey Cohen

if compared then and that factor more one its bit anticipate And you the commercial platform? talk and as platform more, presence about I little ARC intended may. the and a current the X current form versus you to perhaps Could the differences platform

Erez Meltzer

So first I details this all, we of going and within end beginning would of the are the say, give to next next, quarter. of quarter more

the along or is of definitely past we version system, ARC them. are, the And marketed to the FDA our long map last current submit course, the real the expand offering. times going will ARC first We one current it it -- and will the few in road we X as line mentioned which be [indiscernible] not future. first the FDA. of clearance, to the a product in And for after and the not product product is that a have

of locations system. sites more are more or but idea more the is that that. The We spec for to will suitable to give ARC make I the X specific think indications, the available

talking We footprint. about are

whenever are the all, first software us, the cost features the even return the it's enable for about of installed talking be to that the that features. are we're We to going coming to of the on we And it -- are features, beauty of investment, going and the install with remotely. all it, manufacturing,

So we it. from have the do network. send technicians to to don't It's download

Operator

line comes Our AGP. Scott next with from question Henry of the

Scott Henry

What get we Congratulations Could that getting this in Just for questions. it final get to XXX(k) give you Just use general indication. be in to typically line the expect on the a for you is on of approval. review the thoughts sense would application chest what in when indication? time a case? couple may of

Erez Meltzer

I'll me. were and in of the the scans tell the Bear I in the in First hope that I understand conducted all, mind give all and not, question, U.S. answer that now, up you'll that until so the few revenues know We the use when cetera, et installed dozens we talk MSK, the most and common MSK. is chest. especially that of of are the are x-ray mainly chest spine, systems which tomosynthesis. not and hand, about leg, all if

So expect customers ARC definitely than the more sites increase it of system sites we the we in the once that -- clearance, that that -- that, get the take will the and to and likelihood the as is going installed, scans to indications Is of for going this per number used will you stated. be it or... -- be ARC the it increase other is to because what be day will asked

Scott Henry

on, for the that question how to Well, that's I to expect you review long be hoping some sense guess XXX(k)? do very was get the And I helpful. additionally period

Erez Meltzer

COVID. I already cleared system that as will is the guesstimate tell I other time. I hope faster wish it well will since companies us than But as could enhance cannot do be that fact that itself But it the think the I previous you. the I processes the process. and that even experience

Scott Henry

Okay. that's helpful. Well, appreciate.... Would

Erez Meltzer

happy would guesstimate be I to estimate following. the to then longer. give want it I say the reason, thing an I'm not is some that for will because last and will I

be So it it's I that cleared, once the everyone and cleared it's period that will happy take. will to that can imagine announce

Scott Henry

that I Okay. feedback. appreciate

sense providers Have any imaging, installed wanted opportunities the chains, but so of I -- -- mentioned medical, that's what was going just the in in would Nanox.ARC and there X feedback It be? perhaps systems you kind working U.S. the question, you out, may too on expansion how how from and get gotten of Second early service those chains that be far. to X a

Erez Meltzer

in I anatomies people the who beginning or on actually test the the XXXX here, we the on -- on have pilot lot -- encouraged we and the good we the the the that we say, we feedback CT, started to at clinical or call or feedback of system the U.S., the quarter usage, but those on from places the we the that a use the the replacing -- are us of to which this from the a of to beginning, that especially to So of what the lot the soft customers, or the in going mind installation each we're for of would in I they being from customers, the basis, of call feedback. they at the the on places is said parts, of launch body when see it's where end going -- The to it. accelerate clinical examples X, ARC of one and feedback first are this And what and getting decided gain that install used, not the is or think is are we deploy maintenance, do a didn't chains. so only and received pattern and very deployment, far, something a system a the that in

call, on the we the And and will and better probably will is few on good. service overall, them feedback as always next the even the in visibility we would get that installation, indicated, the on So will our today's even in products our I regulatory on processes. always, usage, the very accordingly. process, say improve months, implement we

Scott Henry

quarter? in thinking year? U.S.? the expect tend about question, cadence get QX, expect through to should trying of little Is a in the a the Do Just to they kind to with slower summer Final be months? should any of the fourth sense we're pickup when a QX what seasonality relative we Great. we Okay.

Erez Meltzer

fact due that now, to we Frankly base. especially any expect don't speaking, the up installed are we our seasonality, ramping right

So planning not -- are seasonality results. anyhow But now, expecting we better have effect. we will any right see probably or to

Operator

[Operator Instructions]

Our the comes next from Cantor Ross question Fitzgerald. line with of Osborn

Ross Osborn

can starting So manufacturing seems of in stand? your of the point in where are mind, With initiatives off, contract and capabilities like walk terms it at you you inflection your current through various that deployments.

Erez Meltzer

you're -- said. you So about right what

we In manufacturing, chips, the The have no would problem. I terms of following. say

from high-yield CSEM. of results We that We have able, right available get wafers chips now. to due were we the the

suppliers, is X I and that think an have not We this issue.

tubes tubes, -- already terms are coming In Korea. of we from that the the have

emitter plant tubes the initial prototype is this their but least, coming our not from Europe. And Varex last have completed that We for the are utilizing testing. tube in and has

it into system new be the I shortly, available production. our part that will it and be will So of hope Nanox.ARC integrated

next In of the of moving made terms production that's we're to have site the preparations year capacity higher few is enable than Israel, next in ramp are what assembly of the enable quarters. have the manufacturing arrangement us in we increased needed that manufacturing And doing. we've we the forward, the of the even and up low-cost currently what in we system, the the will to

the with is are on for So say we working to I announced for next line to needed would -- the right that in be it what few seems now, -- next be up ramp quarters later. XXXX

Ross Osborn

adding And the to then any following you U.S. up your us large question. remind for how sales on And plans team? is Would my force today? then previous

Erez Meltzer

it's say, if would I I XX. -- the And with work add now around that are independent people actually right I we altogether. now, then about XX right we think at agents, -- So

in them the XX grow of to future. to expecting number foreseeable the are We

Ross Osborn

And Great. then one for us.... last

Erez Meltzer

that's said to XX XXXX around that, I to be anticipate What for is XX. what we

Ross Osborn

And just reimbursement then Europe And centers us other your lastly, approval, in medical build lastly, of it. market commercialization sales anticipation targeting geographies the you'll terms plan Got you in would there? force it. of of like? leverage walk what be your will own environment or a type you through if looks out what and CE in Got distributor related

Erez Meltzer

Okay.

So there clearance deploy once expected rest you countries few we should and past, to in them we these respect all, remember, that first the have are countries were going to to the agreements that world, are the received. are signed in the with of of a be

So mentioned there I to them, planning ARC. really Mexico to today the visit month they of will be places that coming shortly. are one install very I the next is

were So another this Latin is We America. about countries one. in talking or X X

do CE CE the -- indicated all approval. get the we CE, are of approval, And in the terms countries Once for the we In previously. are we of as in really part the going them. final process the Zealand, It's be work. one we're the Europe, so the we waiting each to that Australia, going New agreements use of were like like to distributors of going to that them, are that signed, like Spain, the

that in mentioned rest to now Israel And have right only the we planning U.S., own you year we in the about ago people. a are the distributors. If and are I U.K., world, remember, the our of to planning have

already plan. in we quarter right touch in distributors have quarter last these order a now that ensure to and are We this in with the

Our few talking countries. and -- each in Europe people already in in we Mexico. of but most each in these now, Right locations in one one, not visited are

about large medium medical to talking centers. are We

Operator

at conclude And showing for participating, you disconnect. further This currently Thank questions no all and today's may you I'm time. this conference call. now does

Nano-X Imaging (NNOX) 20 Aug 242024 Q2 Earnings call transcript